Salahudeen Abdulla K, Kumar Vikas, Madan Niti, Xiao Lianchun, Lahoti Amit, Samuels Joshua, Nates Joseph, Price Kristen
Nephrology Section, Department of General Internal Medicine AT&EC, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Clin J Am Soc Nephrol. 2009 Aug;4(8):1338-46. doi: 10.2215/CJN.02130309. Epub 2009 Jul 23.
Oliguric, hypotensive patients who require large amounts of fluids may benefit from sustained low-efficiency dialysis performed continuously (C-SLED). C-SLED through higher clearance may improve survival, or through greater nutritional loss may worsen survival. No studies have assessed survival on C-SLED. The objective was to examine patient outcomes and survival predictors on C-SLED.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The data of 199 consecutive cancer patients treated with C-SLED were analyzed. The median duration of C-SLED was 50 h. With 48 h of C-SLED, the blood urea nitrogen (BUN) and serum creatinine levels had decreased by 80% and 73%, respectively. The mean arterial pressure (MAP) was maintained despite higher ultrafiltration and reduced vasopressor use. The 30-d mortality rate was 65%. Despite excellent dialysis, the sequential organ failure assessment (SOFA) score remained predictive of mortality. In the univariate model, higher SOFA scores and lower values for MAP, blood pH, and serum albumin and creatinine levels were associated with higher mortality. Administration of total parenteral nutrition (TPN) was, however, associated with lower mortality.
In the multivariate model, the higher SOFA score and lower blood pH, MAP and C-SLED duration were associated with higher mortality. In a subset analysis of 129 patients who received C-SLED for at least 48 h, those with higher BUN levels, which were associated with higher TPN infusion, had a lower mortality risk.
This first detailed report on C-SLED indicates that C-SLED can be effective and suggests a link between nutrition and survival.
对于少尿、低血压且需要大量补液的患者,持续进行的低效透析(C-SLED)可能有益。C-SLED 通过更高的清除率可能提高生存率,或者通过更大的营养损失可能降低生存率。尚无研究评估 C-SLED 治疗患者的生存率。本研究目的是探讨接受 C-SLED 治疗患者的预后及生存预测因素。
设计、地点、参与者及测量指标:分析了 199 例接受 C-SLED 治疗的连续癌症患者的数据。C-SLED 的中位持续时间为 50 小时。进行 48 小时 C-SLED 治疗后,血尿素氮(BUN)和血清肌酐水平分别下降了 80%和 73%。尽管超滤量增加且血管升压药使用减少,但平均动脉压(MAP)仍得以维持。30 天死亡率为 65%。尽管透析效果良好,但序贯器官衰竭评估(SOFA)评分仍可预测死亡率。在单变量模型中,较高的 SOFA 评分以及较低的 MAP、血液 pH 值、血清白蛋白和肌酐水平与较高的死亡率相关。然而,全胃肠外营养(TPN)的使用与较低的死亡率相关。
在多变量模型中,较高的 SOFA 评分以及较低的血液 pH 值、MAP 和 C-SLED 持续时间与较高的死亡率相关。在对 129 例接受 C-SLED 治疗至少 48 小时的患者进行的亚组分析中,BUN 水平较高(与较高的 TPN 输注相关)的患者死亡风险较低。
这份关于 C-SLED 的首份详细报告表明 C-SLED 可能有效,并提示了营养与生存之间的联系。